Literature DB >> 20623246

Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.

Rajni Sethi1, Jeffrey Allen, Bernadine Donahue, Matthias Karajannis, Sharon Gardner, Jeffrey Wisoff, Saroj Kunnakkat, Jeena Mathew, David Zagzag, Kia Newman, Ashwatha Narayana.   

Abstract

Prognosis of diffuse intrinsic pontine gliomas (DIPGs) remains poor. Failure has been predominantly local, with leptomeningeal dissemination (LD) occurring in 4-33% of patients in pre-MRI era series. Routine craniospinal imaging after initial treatment may reveal other relapse patterns relapse. Sixteen consecutive pediatric patients with DIPG treated between 2006 and 2009 were retrospectively reviewed. Treatment regimens, recurrence patterns, survival, and pathologic diagnosis were recorded. Fourteen patients received involved-field radiotherapy to 54 Gy, and two patients received craniospinal irradiation for LD at presentation. Neuraxis MRI was performed at diagnosis and at 4 month intervals following radiotherapy. Fifteen patients have had progression of disease (median progression-free survival 5.0 ± 1.2 months), and 13 patients have died (median survival 9.0 ± 1.4 months). Local failure occurred in 12 patients (75%). LD occurred in nine patients (56%). LD was present at diagnosis in three patients, after initial staging and treatment in six patients, and during autopsy in two patients. Median overall survival was 12.0 ± 3.3 months without LD and 8.0 ± 2.1 months with LD (P = 0.059, log rank test). Median progression-free survival was 9.5 ± 3.9 months without LD and 3.0 ± 2.1 months with LD (P = 0.012, log rank test). The high incidence of LD probably reflects liberal use of spine MRI surveillance. All patients should undergo routine craniospinal imaging at diagnosis and follow-up. Central nervous system prophylaxis should be considered in future clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20623246     DOI: 10.1007/s11060-010-0301-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?

Authors:  C R Freeman; J Kepner; L E Kun; R A Sanford; R Kadota; L Mandell; H Friedman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

Review 2.  Current management of brain stem gliomas.

Authors:  M S Edwards; M Prados
Journal:  Pediatr Neurosci       Date:  1987

3.  Hyperfractionated radiotherapy for children with brainstem gliomas: a pilot study using 7,200 cGy.

Authors:  R J Packer; J C Allen; J L Goldwein; J Newall; R A Zimmerman; J Priest; T Tomita; D E Mandelbaum; B H Cohen; J L Finlay
Journal:  Ann Neurol       Date:  1990-02       Impact factor: 10.422

4.  Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study.

Authors:  A W Walter; A Gajjar; J S Ochs; J W Langston; R A Sanford; L E Kun; R Heideman
Journal:  Med Pediatr Oncol       Date:  1998-01

5.  Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495.

Authors:  C R Freeman; J Krischer; R A Sanford; M E Cohen; P C Burger; L Kun; E C Halperin; I Crocker; M Wharam
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

6.  Hyperfractionated radiotherapy in brain stem tumors: results of a Pediatric Oncology Group study.

Authors:  C R Freeman; J Krischer; R A Sanford; P C Burger; M Cohen; D Norris
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-08       Impact factor: 7.038

7.  Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study.

Authors:  C R Freeman; J P Krischer; R A Sanford; M E Cohen; P C Burger; R del Carpio; E C Halperin; L Munoz; H S Friedman; L E Kun
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-09-30       Impact factor: 7.038

8.  Results of a pilot study of hyperfractionated radiation therapy for children with brain stem gliomas.

Authors:  R J Packer; P A Littman; R M Sposto; G D'Angio; J R Priest; R L Heideman; D A Bruce; D F Nelson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-11       Impact factor: 7.038

9.  Brain stem tumors in children: results of a survey of 62 patients treated with radiotherapy.

Authors:  C R Freeman; S Suissa
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-10       Impact factor: 7.038

10.  Cerebral glioblastoma with cerebrospinal fluid dissemination: a clinicopathological study of 14 cases examined by complete autopsy.

Authors:  K Onda; R Tanaka; H Takahashi; N Takeda; F Ikuta
Journal:  Neurosurgery       Date:  1989-10       Impact factor: 4.654

View more
  23 in total

Review 1.  Diffuse intrinsic pontine glioma: time for therapeutic optimism.

Authors:  Soumen Khatua; Wafik Zaky
Journal:  CNS Oncol       Date:  2014

Review 2.  Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors.

Authors:  Adam L Green; Mark W Kieran
Journal:  Curr Oncol Rep       Date:  2015-03       Impact factor: 5.075

3.  MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry.

Authors:  James L Leach; James Roebker; Austin Schafer; Joshua Baugh; Brooklyn Chaney; Christine Fuller; Maryam Fouladi; Adam Lane; Renee Doughman; Rachid Drissi; Mariko DeWire-Schottmiller; David S Ziegler; Jane E Minturn; Jordan R Hansford; Stacie S Wang; Michelle Monje-Deisseroth; Paul G Fisher; Nicholas G Gottardo; Hetal Dholaria; Roger Packer; Katherine Warren; Sarah E S Leary; Stewart Goldman; Ute Bartels; Cynthia Hawkins; Blaise V Jones
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

4.  B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.

Authors:  Zhiping Zhou; Neal Luther; George M Ibrahim; Cynthia Hawkins; Rajeev Vibhakar; Michael H Handler; Mark M Souweidane
Journal:  J Neurooncol       Date:  2012-12-12       Impact factor: 4.130

Review 5.  Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism.

Authors:  Tammy Hennika; Oren J Becher
Journal:  J Child Neurol       Date:  2015-09-14       Impact factor: 1.987

6.  Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.

Authors:  Kosuke Funato; Tamara Major; Peter W Lewis; C David Allis; Viviane Tabar
Journal:  Science       Date:  2014-11-20       Impact factor: 47.728

Review 7.  Diffuse intrinsic pontine glioma-current status and future strategies.

Authors:  Soumen Khatua; Kevin R Moore; Tribh S Vats; John R W Kestle
Journal:  Childs Nerv Syst       Date:  2011-04-30       Impact factor: 1.475

8.  Human pontine glioma cells can induce murine tumors.

Authors:  Viola Caretti; A Charlotte P Sewing; Tonny Lagerweij; Pepijn Schellen; Marianna Bugiani; Marc H A Jansen; Dannis G van Vuurden; Anna C Navis; Ilona Horsman; W Peter Vandertop; David P Noske; Pieter Wesseling; Gertjan J L Kaspers; Javad Nazarian; Hannes Vogel; Esther Hulleman; Michelle Monje; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2014-04-29       Impact factor: 17.088

Review 9.  Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review.

Authors:  Chloé Louise Gelder; Cynthia Hawkins; Michal Zapotocky; Peter Dirks; Ute Bartels; Eric Bouffet
Journal:  Childs Nerv Syst       Date:  2019-01-31       Impact factor: 1.475

Review 10.  Novel therapeutic delivery approaches in development for pediatric gliomas.

Authors:  Katherine E Warren
Journal:  CNS Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.